Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-Asparaginase with Hyper-CVAD in Adult ALL
NCT01005914Phase 2Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jun 2009
- Primary completion
- Mar 2013
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegaspargase in acute lymphoblastic leukemia (ALL), sponsored by OHSU Knight Cancer Institute. Primary endpoints: Complete Response Rate After Course 1 of Pegaspargase When Administered in Combination With Hyper-CVAD Regimen and Grade 3 and 4 Toxicity Associated With the Combination of Peg-Asparaginase and Hyper-CVAD. Started Jun 2009; status: terminated.
02
Drugs
pegaspargase
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01005914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01005914.